A Personal Prospective on Testosterone Therapy in Women-What We Know in 2022.
Level 5 - mechanism / opinion, no new human data
Narrative review and personal perspective without primary data or systematic search methodology.
PubMed 35893288 · doi:10.3390/jpm12081194
What was done
This is a narrative perspective and review addressing the safety profile, potential indications, and regulatory status of testosterone therapy in perimenopausal and postmenopausal women. No primary experimental design or systematic review methodology is described in the abstract.
What was found
The abstract provides no primary quantitative data or statistical effect sizes. It highlights a regulatory disparity (more than 30 FDA-approved testosterone options for men versus zero for women) and references external literature suggesting benefits for sexual function, osteoporosis prevention, neuroprotection, and breast cancer incidence reduction, alongside 7-year safety data for subcutaneous pellets.
Why it matters
The paper presents an argument for regulatory agencies, such as the US FDA, to establish approved testosterone formulations specifically for testosterone-deficient women.
Limits
The article represents an expert opinion and narrative commentary without primary data or systematic appraisal. Specific study details, sample sizes, confounder adjustments, and effect estimates for the referenced cohort studies are absent from the abstract.
Cited by
- supports There are no FDA-approved testosterone medications specifically for women in the United States.